peramivir and Brain-Diseases

peramivir has been researched along with Brain-Diseases* in 3 studies

Other Studies

3 other study(ies) available for peramivir and Brain-Diseases

ArticleYear
Successful Outcome in an Adult Patient with Influenza-associated Hemorrhagic Shock and Encephalopathy Syndrome.
    Internal medicine (Tokyo, Japan), 2020, Sep-15, Volume: 59, Issue:18

    A 50-year-old woman presented with coma and hemorrhagic shock. A rapid influenza antigen test revealed influenza A infection; other laboratory examinations ruled out any other suspected infections. She was diagnosed with hemorrhagic shock and encephalopathy syndrome (HSES) induced by influenza A. She was administered methylprednisolone pulse therapy and peramivir. Subsequently, she was discharged without any sequelae. Only a few cases of influenza-induced HSES have been reported, and the clinical outcomes were very poor. We herein report a successfully treated adult case of influenza-induced HSES and review this rare syndrome.

    Topics: Acids, Carbocyclic; Anti-Inflammatory Agents; Antiviral Agents; Blood Coagulation Disorders; Brain Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female; Guanidines; Humans; Influenza A virus; Influenza, Human; Methylprednisolone; Middle Aged; Shock, Hemorrhagic; Syndrome

2020
Encephalopathy Associated with Influenza B in a Healthy Young Man.
    Internal medicine (Tokyo, Japan), 2017, Volume: 56, Issue:14

    A 19-year-old man presented with a fever, convulsions, and loss of consciousness at our hospital. The patient had a Glasgow Coma Scale score of 12. Influenza B virus infection was diagnosed using the rapid test kit, and an eight-fold increase in the serum levels of anti-influenza B virus antibody was confirmed using the complement fixation test. Brain magnetic resonance imaging showed multifocal high-signal lesions, and an electroencephalogram showed diffuse slowing of the background activity, indicating acute encephalopathy. After treatment with peramivir and methylprednisolone for 3 days, the patient was discharged without any neurological impairment. This was a case of influenza B infection associated with acute encephalopathy in a healthy young man.

    Topics: Acids, Carbocyclic; Antibodies, Viral; Brain Diseases; Cyclopentanes; Electroencephalography; Guanidines; Humans; Influenza B virus; Influenza, Human; Magnetic Resonance Imaging; Male; Methylprednisolone; Young Adult

2017
Neuropathology of H5N1 virus infection in ferrets.
    Veterinary microbiology, 2012, May-04, Volume: 156, Issue:3-4

    Highly pathogenic H5N1 virus remains a potential threat to humans. Over 289 fatalities have been reported in WHO confirmed human cases since 2003, and lack of effective vaccines and early treatments contribute to increasing numbers of cases and fatalities. H5N1 encephalitis is a recognized cause of death in Vietnamese cases, and brain pathology is described in other human cases and naturally infected animals. However, neither pathogenesis of H5N1 viral infection in human brain nor post-infection effects in survivors have been fully investigated. We report the brain pathology in a ferret model for active infection and 18-day survival stages. This model closely resembles the infection pattern and progression in human cases of influenza A, and our report is the first description of brain pathology for longer term (18-day) survival in ferrets. We analyzed viral replication, type and severity of meningoencephalitis, infected cell types, and cellular responses to infection. We found viral replication to very high titers in ferret brain, closely correlating with severity of meningoencephalitis. Viral antigens were detected predominantly in neurons, correlating with inflammatory lesions, and less frequently in astrocytes and ependymal cells during active infection. Mononuclear cell infiltrates were observed in early stages predominantly in cerebral cortex, brainstem, and leptomeninges, and less commonly in cerebellum and other areas. Astrogliosis was mild at day 4 post-infection, but robust by day 18. Early and continuous treatment with an antiviral agent (peramivir) inhibited virus production to non-detectable levels, reduced severity of brain injury, and promoted higher survival rates.

    Topics: Acids, Carbocyclic; Animals; Antigens, Viral; Antiviral Agents; Astrocytes; Brain Diseases; Central Nervous System; Cyclopentanes; Cytokines; Ferrets; Guanidines; Influenza A Virus, H5N1 Subtype; Meningoencephalitis; Neuraminidase; Orthomyxoviridae Infections; Virus Replication

2012